Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Bigginvestoron Apr 13, 2021 4:05pm
219 Views
Post# 32987026

RE:Andrew Salzman Interview

RE:Andrew Salzman Interview
indaknownewfie wrote: Was absolutely fantastic. Loved hearing how this is going to scale up. The science is there. Adding Sepsis as an indication is going to be huge. So according to the CDC the cost of Sepsis last year was 28 Billion Dollars in the US alone. The Province of Ontario, Canada spent a billion dollars alone last year. If one were to consider the potential global market for this indication alone, reflect on what the market cap could be then. Of course it won't go there overnight and i predict this company will be bought out by big pharma before that happens. At any rate,  diamond hands will likely make $$$$. I'm staying long with my position. People can choose to believe what they wish, that's their right and their money. 


how much will you sell at ??
<< Previous
Bullboard Posts
Next >>